Antimicrobial Spectrum Comparison of Ceftriaxone and Cefoperazone/Sulbactam
Clinical Applications and Advantages
- The Infectious Diseases Society of America recommends cefoperazone/sulbactam for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) where broader coverage is needed, particularly for infections with high risk of multidrug-resistant organisms 1
- Ceftriaxone is appropriate for community-acquired infections of mild-to-moderate severity, according to the Infectious Diseases Society of America 2
- Cefoperazone/sulbactam is preferred for healthcare-associated infections and those with risk factors for resistant pathogens, as suggested by the World Journal of Emergency Surgery 4
Antimicrobial Resistance Considerations
- For empiric therapy in settings with high prevalence of ESBL-producing organisms, cefoperazone/sulbactam would be more appropriate, due to its protection against beta-lactamase-mediated resistance, as recommended by the World Journal of Emergency Surgery 4
Clinical Decision-Making Algorithm
- For community-acquired infections in stable patients with low risk of resistant pathogens, ceftriaxone may be sufficient, according to the Infectious Diseases Society of America 2
- For healthcare-associated infections or patients with risk factors for resistant pathogens, the Journal of Microbiology, Immunology and Infection suggests choosing cefoperazone/sulbactam 1
- For intra-abdominal infections, especially those involving anaerobes, cefoperazone/sulbactam provides better coverage, as recommended by the World Journal of Emergency Surgery 4